Morning Report

More documents

Recommendations

Info

Please make your selection... A. Azathioprine B. Infliximab C. Mesalamine (topical) D. Metronidazole E. Prednisone 20% 20% 20% 20% 20% A. B. C. D. E.
MKSAP Ulcerative colitis can be classified by both extent and severity of disease, and treatment is guided by both factors. This patient has mild to moderate ulcerative proctitis, with disease limited to the distal rectum. Therefore, the best treatment would be local therapy with suppositories or enemas. Options include cortisone foam and mesalamine or corticosteroid suppositories for proctitis and hydrocortisone or mesalamine enemas for left-sided colitis. Topical mesalamine is more effective than topical corticosteroids, and almost half of the dose of topical corticosteroids may be absorbed systemically, leading to adverse long-term side effects. Maintenance of remission can be achieved with topical mesalamine.
Page 1 and 2: Morning Report November 21 2011 Joh
Page 3 and 4: MKSAP On physical examination, the
Page 5: MKSAP Which of the following is the
Page 9 and 10: HPI 36 M with a h/o AML s/p stem ce
Page 11 and 12: Physical Exam Temp 36.5, HR 142, BP
Page 13 and 14: Acute Diarrhea - Differential Infec
Page 15 and 16: Initial Labs?
Page 17 and 18: Management, further workup? Acute D
Page 19 and 20: Diarrhea + Abd pain, > 5 days • N
Page 21 and 22: Graft Versus Host Disease - Present
Page 23 and 24: Graft Versus Host Disease - Diagnos
Page 25 and 26: Hill GR, Ferrara JLM. The primacy o
Page 27 and 28: Our patient Supportive treatment St
Page 29: Repeat Colonoscopy Diffuse moderate
Page 32 and 33: Crohn's colitis after stem cell tra
Page 34: Take Home Points • Understand the

Morning Report

Create successful ePaper yourself

Delete template?

Save as template?